DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Thalitone (Chlorthalidone) - Published Studies

 
 



Thalitone Related Published Studies

Well-designed clinical trials related to Thalitone (Chlorthalidone)

Spironolactone and chlorthalidone in uncontrolled elderly hypertensive patients treated with calcium antagonists and angiotensin II receptor-blocker: effects on endothelial function, inflammation, and oxidative stress. [2009.10]

Antihypertensive efficacy of metoprolol XL/low dose chlorthalidone (6.25 mg) combination: a randomized, comparative study in indian patients with mild-to-moderate essential hypertension. [2009.07.22]

A randomized, comparative study evaluating the efficacy and tolerability of losartan-low dose chlorthalidone (6.25 mg) combination with losartan-hydrochlorothiazide (12.5 mg) combination in Indian patients with mild-to-moderate essential hypertension. [2009.07]

Differential effects of chlorthalidone versus spironolactone on muscle sympathetic nerve activity in hypertensive patients. [2009.04]

Cost-effectiveness of chlorthalidone, amlodipine, and lisinopril as first-step treatment for patients with hypertension: an analysis of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). [2008.05]

Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure. [2006.03]

Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril. [2005.04.06]

Well-designed clinical trials possibly related to Thalitone (Chlorthalidone)

The effect of antihypertensive agents on sleep apnea: protocol for a randomized controlled trial. [2014]

Blood pressure control and cardiovascular outcomes in normal-weight, overweight, and obese hypertensive patients treated with three different antihypertensives in ALLHAT. [2014]

Clinical significance of incident hypokalemia and hyperkalemia in treated hypertensive patients in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. [2012]

Prevention of hypertension in patients with pre-hypertension: protocol for the PREVER-prevention trial. [2011.03.05]

A comparison between diuretics and angiotensin-receptor blocker agents in patients with stage I hypertension (PREVER-treatment trial): study protocol for a randomized double-blind controlled trial. [2011.02.24]

Pharmacogenetic effect of the stromelysin (MMP3) polymorphism on stroke risk in relation to antihypertensive treatment: the genetics of hypertension associated treatment study. [2011.02]

Pharmacogenetic effect of the stromelysin (MMP3) polymorphism on stroke risk in relation to antihypertensive treatment: the genetics of hypertension associated treatment study. [2011]

Antioxidative effects of thiazide diuretics in refractory hypertensive patients. A randomized crossover trial of chlortalidone and trichlormethiazide. [2010]

Atrial fibrillation at baseline and during follow-up in ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial). [2009.11.24]

Heart failure in ALLHAT: did blood pressure medication at study entry influence outcome? [2009.09]

Antihypertensive pharmacogenetic effect of fibrinogen-beta variant -455G>A on cardiovascular disease, end-stage renal disease, and mortality: the GenHAT study. [2009.06]

ALLHAT findings revisited in the context of subsequent analyses, other trials, and meta-analyses. [2009.05.11]

Changes in serum potassium mediate thiazide-induced diabetes. [2008.12]

Heart failure with preserved and reduced left ventricular ejection fraction in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. [2008.11.25]

Blood pressure control by drug group in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). [2008.10]

Effects of antihypertensive drug treatment on the risk of dementia and cognitive impairment. [2008.03]

Clinical outcomes by race in hypertensive patients with and without the metabolic syndrome: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). [2008.01.28]

Blood pressure control in Hispanics in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. [2007.11]

Sex-specific effects of AGT-6 and ACE I/D on pulse pressure after 6 months on antihypertensive treatment: the GenHAT study. [2007.11]

The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Heart Failure Validation Study: diagnosis and prognosis. [2007.01]

Antihypertensive efficacy and safety of manidipine versus amlodipine in elderly subjects with isolated systolic hypertension: MAISH study. [2007]

Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). [2006.11.13]

Additional antihypertensive effect of drugs in hypertensive subjects uncontrolled on diltiazem monotherapy: a randomized controlled trial using office and home blood pressure monitoring. [2006.10]

Incidence and predictors of angioedema in elderly hypertensive patients at high risk for cardiovascular disease: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). [2006.09]

Role of diuretics in the prevention of heart failure: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. [2006.05.09]

Cardiovascular outcomes in high-risk hypertensive patients stratified by baseline glomerular filtration rate. [2006.02.07]

Pharmacogenetic association of the angiotensin-converting enzyme insertion/deletion polymorphism on blood pressure and cardiovascular risk in relation to antihypertensive treatment: the Genetics of Hypertension-Associated Treatment (GenHAT) study. [2005.06.28]

Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). [2005.06.27]

Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). [2005.04.25]

Comparison of antihypertensive effects of an angiotensin-converting enzyme inhibitor, a calcium antagonist and a diuretic in patients with hypertension not controlled by angiotensin receptor blocker monotherapy. [2005.04]

Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes. [2005.01.01]

Other research related to Thalitone (Chlorthalidone)

Efficacy of azilsartan medoxomil with chlorthalidone in hypertension. [2014]

Effect of chlorthalidone, amlodipine, and lisinopril on visit-to-visit variability of blood pressure: results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. [2014]

Azilsartan medoxomil/chlorthalidone: a new fixed-dose combination antihypertensive. [2013]

Spironolactone prevents chlorthalidone-induced sympathetic activation and insulin resistance in hypertensive patients. [2012]

Blood pressure-lowering efficacy of the fixed-dose combination of azilsartan medoxomil and chlorthalidone: a factorial study. [2012]

Chlorthalidone compared with hydrochlorothiazide in reducing cardiovascular events: systematic review and network meta-analyses. [2012]

Long-Term Effects of Chlorthalidone Versus Hydrochlorothiazide on Electrocardiographic Left Ventricular Hypertrophy in the Multiple Risk Factor Intervention Trial. [2011.12]

Chlorthalidone improves vertebral bone quality in genetic hypercalciuric stone-forming rats. [2011.08]

Chlorthalidone reduces cardiovascular events compared with hydrochlorothiazide: a retrospective cohort analysis. [2011.04]

Association between chlorthalidone treatment of systolic hypertension and long-term survival. [2011]

Renewed interest in chlorthalidone: evidence from the Veterans Health Administration. [2010.12]

Meta-analysis of dose-response characteristics of hydrochlorothiazide and chlorthalidone: effects on systolic blood pressure and potassium. [2010.04]

Hydrochlorothiazide versus chlorthalidone in the management of hypertension. [2010.01]

[Chlorthalidone better than hydrochlorothiazide in hypertension] [2010]

Development and validation of a reversed-phase high-performance liquid chromatographic method for the simultaneous determination of amiloride hydrochloride, atenolol, hydrochlorothiazide, and chlorthalidone in their combined mixtures. [2009.03]

DIFFERENTIAL EFFECTS OF CHLORTHALIDONE VS. SPIRONOLACTONE ON MUSCLE SYMPATHETIC NERVE ACTIVITY IN HYPERTENSIVE PATIENTS. [2009.01.21]

Should chlorthalidone be the diuretic of choice for antihypertensive therapy? [2008.08]

Clinical effectiveness of low-dose chlorthalidone (6.25 mg) + atenolol combination in stage I hypertensive patients: a multicenter, randomized, controlled study. [2008.06]

Metabolic and clinical outcomes in nondiabetic individuals with the metabolic syndrome assigned to chlorthalidone, amlodipine, or lisinopril as initial treatment for hypertension: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). [2008.02]

Chlorthalidone inhibits the KvLQT1 potassium current in guinea-pig ventricular myocytes and oocytes from Xenopus laevis. [2008.02]

Cost-effectiveness of Chlorthalidone, Amlodipine, and Lisinopril as First-step Treatment for Patients with Hypertension: An Analysis of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). [2008.01.29]

Metabolic and Clinical Outcomes in Non-Diabetic Individuals with the Metabolic Syndrome Assigned to Chlorthalidone, Amlodipine, or Lisinopril as Initial Treatment for Hypertension: A Report from the ALLHAT Study. [2007.11.13]

Drug-induced acute myopia following chlorthalidone treatment. [2007.09]

Chlorthalidone improves endothelial-mediated vascular responses in hypertension complicated by nondiabetic metabolic syndrome. [2005.12]

Other possibly related research studies

Survival of severe amlodipine intoxication due to medical intensive care. [2006.09.12]

Antihypertensive therapy, the alpha-adducin polymorphism, and cardiovascular disease in high-risk hypertensive persons: the Genetics of Hypertension-Associated Treatment Study. [2006.05.16]

Thiazide diuretics in the treatment of hypertension: an update. [2006.04]

Role of angiotensin II receptor blockers in atherosclerotic plaque stability. [2006.02]

[Diuretic therapy in heart failure] [2006.01]

Does ALLHAT change the management of hypertension in chronic kidney disease? [2005.12]

An economic evaluation of the 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of mild-to-moderate hypertension in Greece. [2005.09]

ALLHAT in perspective: implications to clinical practice and clinical trials. [2005.06]

Systemic hypertension. [2007.04]

Antihypertensive therapy, the alpha-adducin polymorphism, and cardiovascular disease in high-risk hypertensive persons: the Genetics of Hypertension-Associated Treatment Study. [2007.03]

Pharmacoepidemiology of antihypertensive drugs in primary care setting of Bahrain between 1998 and 2000. [2006.10]

Low-dose aldosterone blockade as a new treatment paradigm for controlling resistant hypertension. [2007.01]

Antihypertensive therapy, the alpha-adducin polymorphism, and cardiovascular disease in high-risk hypertensive persons: the Genetics of Hypertension-Associated Treatment Study. [2007.04]

Sex-Specific Effects of AGT-6 and ACE I/D on Pulse Pressure After 6 Months on Antihypertensive Treatment: The GenHAT Study. [2007.06.30]

[Antihypertensive therapy and renoprotection: do we really need to block the renin-angiotension system?] [2007.09]

Sex-Specific Effects of AGT-6 and ACE I/D on Pulse Pressure After 6 Months on Antihypertensive Treatment: The GenHAT Study. [2007.10]

Long-term fatal outcomes in subjects with stroke or transient ischemic attack: fourteen-year follow-up of the systolic hypertension in the elderly program. [2008.04]

Pharmacogenetic association of the NPPA T2238C genetic variant with cardiovascular disease outcomes in patients with hypertension. [2008.01.23]

Improving care in resistant hypertension: medication trends and nonpharmacologic strategies in a specialty clinic. [2007]

Atrial fibrillation and isolated systolic hypertension: the systolic hypertension in the elderly program and systolic hypertension in the elderly program-extension study. [2008.06]

Diuretics: from classical carbonic anhydrase inhibitors to novel applications of the sulfonamides. [2008]

Resistant hypertension and hyperaldosteronism. [2008.12]

Simultaneous determination of losartan and hydrochlorothiazide in human plasma by LC/MS/MS with electrospray ionization and its application to pharmacokinetics. [2009.07]

Diuretics: still essential drugs for the management of hypertension. [2009.06]

Improvement of diastolic function after regression of left ventricular hypertrophy. [2008.10]

[Serum uric acid prevalence and changes post various antihypertensive agents in patients with essential hypertension] [2008.06]

The Evidence-Based Use of Thiazide Diuretics in Hypertension and Nephrolithiasis. [2010.08.26]

Thiazides diuretics in the treatment of nephrolithiasis: are we using them in an evidence-based fashion? [2010.08.25]

Pharmacogenetic association of hypertension candidate genes with fasting glucose in the GenHAT Study. [2010.10]

Treatment of resistant hypertension. [2009.12]

[When do combinations of diuretics make sense?] [2009.11]

The Association between Hypertension and Dementia in the Elderly. [2012]

Long-Term follow-up of participants with heart failure in the Antihypertensive and Lipid-lowering Treatment to Prevent Heart Attack Trial (ALLHAT). [2011.10.25]

Half a century of hydrochlorothiazide: facts, fads, fiction, and follies. [2011.10]

Pharmacogenetic associations of MMP9 and MMP12 variants with cardiovascular disease in patients with hypertension. [2011]

[Why do good drugs disappear?]. [2010.10]

Evidence-based diuretic therapy for improving cardiovascular prognosis in systemic hypertension. [2011.04.15]

The evidence-based use of thiazide diuretics in hypertension and nephrolithiasis. [2010.10]

Thiazides diuretics in the treatment of nephrolithiasis: are we using them in an evidence-based fashion? [2011.09]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017